View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 10, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Caladrius Biosciences, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		8,940,857

Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 11,997,606	$ 14,705,008
Accounts receivable, net of allowances of $0 at March 31, 2017 and December 31, 2016, respectively	3,168,756	2,891,723
Deferred costs	3,538,641	3,582,298
Prepaid and other current assets	3,228,845	3,469,932
Total current assets	21,933,848	24,648,961
Property, plant and equipment, net	16,760,376	17,149,241
Goodwill	7,013,315	7,013,315
Intangible assets, net	2,165,380	2,307,880
Other assets	655,503	713,451
Total assets	48,528,422	51,832,848
Current Liabilities
Accounts payable	3,578,045	4,366,753
Accrued liabilities	5,061,813	6,062,569
Liabilities of Business Transferred under Contractual Arrangement, Current	5,000,000	0
Long-term debt, current	3,193,365	3,126,457
Notes payable, current	1,014,495	847,327
Unearned revenues, current	5,364,662	5,098,193
Total current liabilities	23,212,380	19,501,299
Deferred income taxes	1,120,231	1,070,700
Notes payable	215,985	292,217
Unearned revenues - long-term	4,447,397	4,587,397
Long-term debt	1,701,022	2,524,897
Other long-term liabilities	407,241	389,858
Total liabilities	31,104,256	28,366,368
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests	19,400,000	19,400,000
Stockholders' Equity (Deficit)
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2017 and December 31, 2016	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 8,953,312 and 8,205,791 shares, at March 31, 2017 and December 31, 2016, respectively	8,953	8,206
Additional paid-in capital	414,056,246	410,372,049
Treasury stock, at cost; 11,080 shares at March 31, 2017 and December 31, 2016, respectively	(707,637)	(707,637)
Accumulated deficit	(414,148,636)	(404,788,809)
Total Caladrius Biosciences, Inc. stockholders' equity (deficit)	(790,974)	4,883,909
Noncontrolling interests	(1,184,860)	(817,429)
Total equity (deficit)	(1,975,834)	4,066,480
Liabilities and Equity, Total	$ 48,528,422	$ 51,832,848

Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable trade, net of allowance for doubtful accounts	$ 0	$ 0
Preferred Stock, authorized	20,000,000	20,000,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	1	1
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	8,953,312	8,205,791
Common Stock, Shares, Outstanding	8,953,312	8,205,791
Treasury stock (shares)	11,080	11,080

Consolidated Statements of Operations - USD ($)	3 Months Ended
Consolidated Statements of Operations - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Revenues	$ 7,922,667	$ 7,489,479
Cost of revenues	8,042,265	6,228,256
Research and development	3,462,905	5,876,178
Selling, general, and administrative	5,949,180	6,458,331
Total operating costs and expenses	17,454,350	18,562,765
Operating loss	(9,531,683)	(11,073,286)
Other income (expense):
Other income (expense), net	(44,395)	5,685
Interest expense	(167,715)	(926,817)
Nonoperating Income (Expense), Total	(212,110)	(921,132)
Loss before provision for income taxes and noncontrolling interests	(9,743,793)	(11,994,418)
Provision for income taxes	49,531	53,378
Net loss	(9,793,324)	(12,047,796)
Less - loss attributable to noncontrolling interests	(433,497)	(66,879)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (9,359,827)	$ (11,980,917)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (1.12)	$ (2.09)
Weighted average common shares outstanding	8,386,903	5,738,044

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Net loss	$ (9,793,324)	$ (12,047,796)
Available for sale securities - net unrealized loss	0	(486)
Total other comprehensive loss	0	(486)
Comprehensive loss	(9,793,324)	(12,048,282)
Comprehensive loss attributable to noncontrolling interests	(433,497)	(66,879)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (9,359,827)	$ (11,981,403)

Consolidated Statements of Equity - USD ($)	Total	Total NeoStem, Inc. Shareholders' Equity [Member]	Series B Convertible Preferred Stock Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2015			10,000	5,673,302
Beginning Balance at Dec. 31, 2015	$ 23,283,824	$ 23,713,533	$ 100	$ 5,673	$ 396,547,401	$ 486	$ (372,132,490)	$ (707,637)	$ (429,709)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(12,047,796)	(11,980,917)					(11,980,917)		(66,879)
Unrealized gain/loss on marketable securities	(486)	(486)
Share-based compensation (in shares)				92,181
Share-based compensation	851,245	851,245		$ 92	851,153
Proceeds from issuance of common stock (in shares)				146,844
Net proceeds from issuance of common stock	1,096,208	1,096,208		$ 147	1,096,061
Change in Ownership in Subsidiary	0	(17,815)			(17,815)				17,815
Ending Balance at Mar. 31, 2016	13,182,995	13,661,768	$ 100	$ 5,912	398,476,800	0	(384,113,407)	(707,637)	(478,773)
Ending Balance (shares) at Mar. 31, 2016			10,000	5,912,327
Beginning Balance (shares) at Dec. 31, 2016			10,000	8,205,790
Beginning Balance at Dec. 31, 2016	4,066,480	4,883,909	$ 100	$ 8,206	410,372,049	0	(404,788,809)	(707,637)	(817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(9,793,324)	(9,359,827)					(9,359,827)		(433,497)
Share-based compensation (in shares)				113,287
Share-based compensation	509,550	509,550		$ 113	509,437
Proceeds from issuance of common stock (in shares)				634,235
Net proceeds from issuance of common stock	3,241,460	3,241,460		$ 634	3,240,826
Change in Ownership in Subsidiary	0	(66,066)			(66,066)				66,066
Ending Balance at Mar. 31, 2017	$ (1,975,834)	$ (790,974)	$ 100	$ 8,953	$ 414,056,246	$ 0	$ (414,148,636)	$ (707,637)	$ (1,184,860)
Ending Balance (shares) at Mar. 31, 2017			10,000	8,953,312

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (9,793,324)	$ (12,047,796)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	533,198	851,246
Depreciation and amortization	655,340	737,158
Loss on disposal of assets	47,301	591,307
Deferred income taxes	49,531	53,378
Changes in operating assets and liabilities:
Prepaid and other current assets	241,087	(116,610)
Accounts receivable	(277,033)	(46,730)
Deferred costs	43,657	(1,074,435)
Unearned revenues	126,468	3,069,840
Other assets	57,968	81,754
Accounts payable, accrued liabilities and other liabilities	(1,772,101)	(127,410)
Net cash used in operating activities	(10,087,908)	(8,028,298)
Cash flows from investing activities:
Acquisition of property, plant and equipment	(171,276)	(1,044,827)
Net cash used in investing activities	(171,276)	(1,044,827)
Cash flows from financing activities:
Payments Related to Tax Withholding for Share-based Compensation	(23,647)	0
Net proceeds from issuance of common stock	3,241,460	1,096,208
Repayment of long-term debt	(756,966)	(6,348,646)
Proceeds from notes payable	400,998	368,615
Repayment of notes payable	(310,063)	(335,297)
Proceeds From Licensing Agreements, Milestone Payments	5,000,000	0
Sale of ownership interest in subsidiary	0	19,400,000
Net cash provided by financing activities	7,551,782	14,180,880
Net (decrease) increase in cash and cash equivalents	(2,707,402)	5,107,755
Cash and cash equivalents at beginning of period	14,705,008	20,318,411
Cash and cash equivalents at end of period	11,997,606	25,426,166
Cash paid during the period for:
Interest	130,204	973,729
Proceeds from Stock Options Exercised	0	0
Proceeds from exercise of warrants	0	$ 0
Hitachi Chemical Co., LTD [Member]
Cash flows from financing activities:
Proceeds From Licensing Agreements, Milestone Payments	$ (5,000,000)

The Business

3 Months Ended

Mar. 31, 2017

The Business [Abstract]

The Business

Overview

Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”), is a company developing cellular therapeutics to treat certain diseases. We leverage specialized cell therapy clinical development expertise to select and develop early-stage cell therapy candidates with the intention of partnering these candidates post proof-of-concept in humans. Our current lead product candidate, CLBS03, is an autologous polyclonal T regulatory cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("TID"). Our subsidiary, PCT, LLC, a Caladrius Company^TM("PCT"), is a well-known provider of development and manufacturing services to the cell and cell-based gene therapy industry. PCT has significant cell therapy-specific experience and expertise, an expansive list of noteworthy clients and significant revenue growth over the past three years. Notably, PCT and Hitachi Chemical Co. America, Ltd. ("Hitachi America") and Hitachi Chemical Co., Ltd. ("Hitachi and, together with Hitachi America, "Hitachi Chemical") are engaged in a strategic collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise.

Proposed Sale of Remaining Interest in PCT to Hitachi America

On March 16, 2017 (the "Effective Date"), Caladrius entered into an interest purchase agreement (the "Purchase Agreement"), by and among Caladrius, PCT and Hitachi America, pursuant to which Hitachi America agreed to acquire the 80.1% membership interest in PCT that it does not already own from Caladrius for $75.0 million in cash (the "Sale"), subject to potential adjustment, including based on PCT’s cash and outstanding indebtedness as of the closing of the Sale, a potential future milestone payment of $5.0 million based on PCT's revenue in 2017-2018 and certain transaction expenses (the "Purchase Price"). Pursuant to the terms of the Purchase Agreement, on the Effective Date, Hitachi America paid Caladrius $5.0 million of the Purchase Price (the "Initial Payment"). At the closing of the Sale (the "Closing"), an additional $5.0 million of the Purchase Price will be deposited into an escrow account to cover potential indemnification claims against Caladrius. The Closing is subject to customary closing conditions, including approval of Caladrius’ stockholders, and is expected to occur in May 2017. However, we cannot provide assurance as to when the Sale will be completed, or whether it will be completed at all.

As part of the Purchase Price, Hitachi will pay Caladrius $5.0 million (the "Milestone Payment") if PCT achieves $125.0 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018. For purposes of the Milestone Payment, “Cumulative Revenue” will be calculated based on PCT’s revenue from all customers (including Caladrius and its subsidiaries) in accordance with the financial accounting and reporting standards set forth in the statements and pronouncements of the Financial Accounting Standards Board ("FASB"), consistently applied.

PCT is a well-known cell therapy development and manufacturing provider (often called a contract development and manufacturing organization, or "CDMO"), specializing in cell and cell-based gene therapies. PCT offers high-quality development and manufacturing capabilities (e.g., current Good Manufacturing Practice ("cGMP") manufacturing systems and facilities), quality systems, cell and tissue processing, logistics, storage and distribution) and engineering solutions (e.g., process and assay development, optimization and automation) to clients with therapeutic candidates at all stages of development. PCT produces clinical supplies and expects to produce commercial product for its clients in the future. Following completion of the Sale, we will no longer be involved in the CDMO business, but will continue to develop cell therapy product candidates (the "Retained Business").

CLBS03

We are developing strategically, through the utilization of our core development and manufacturing expertise, a product candidate that is an innovative therapy for TID. This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be below the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells; the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the T effector cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments, only lifelong insulin therapy, which therapy often does not prevent serious co-morbidities. Two Phase 1 clinical trials of this technology in T1D demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis of early therapeutic effect is planned after approximately 50% of patients reach the six-month follow-up milestone, which analysis is expected in late 2017 or early 2018. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA").

Ischemic Repair (CD34 Cell Technology)

Our CD34 cell technology has led to the development of therapeutic candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating CLBS12 (a candidate for CLI) was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed with PMDA and, if successful, could provide the basis for conditional approval under Japan's favorable regenerative medicine law. We are seeking to collaborate on CLBS12 with development and/or manufacturing partners. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for additional clinical indications in the United States and expect to learn the results of those applications in the first half of 2017.

We intend to develop this platform if capital becomes available through grants, partnerships or licensing, as well as potentially using reasonable amounts of our own capital as it becomes available.

Additional Out-licensing Opportunities

Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product, additional indications for our CD34 cell technology and a platform using tumor cell/dendritic cell technology for immuno-oncology application. The immuno-oncology program has the benefit of promising Phase 2 clinical data and applicability to multiple indications. This platform is based on our extensive intellectual property portfolio. In 2016, we completed multiple out-licensing agreements for this and other technology platforms in an effort to monetize non-core assets.

Our long-term strategy focuses on advancing cell-based therapies to the market and assisting patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on demonstration of proof-of-concept in man as well as process and manufacturing advancements.

Cell Therapy Development and Manufacturing

PCT is a well-known CDMO, specializing in cell and cell-based gene therapies. PCT offers high-quality development and manufacturing capabilities (e.g., cGMP manufacturing systems and facilities, quality systems, cell and tissue processing, logistics, storage and distribution) and engineering solutions (e.g., process and assay development, optimization and automation) to clients with therapeutic candidates at all stages of development. PCT produces clinical supplies and ultimately, intends also to produce commercial product for its clients. PCT has worked with over 100 clients and produced over 20,000 cell therapy products since it was founded 18 years ago. PCT’s manufacturing services are designed to reduce the capital investment and time required by clients to advance their development programs compared to conducting process development and manufacturing in-house. PCT has demonstrated regulatory expertise, including the support of over 50 U.S. and European Union ("EU") regulatory filings for clients and expertise across multiple cell types and therapeutic applications, including immunotherapy (e.g. CAR-T therapies), neuro/endocrine therapies, hematopoietic replacement and tissue repair/regeneration. PCT offers a complete development pathway for its clients, with services supporting preclinical through commercial phase, all underpinned by timely process optimization and automation support. PCT currently operate facilities qualified under cGMPs in each of Allendale, New Jersey and Mountain View, California, including EU-compliant production capacity in the Allendale facility. On March 11, 2016, PCT entered into a technology license agreement with Hitachi (the "Hitachi License Agreement") to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise, at which time Caladrius sold 19.9% of its ownership stake in PCT to Hitachi. As discussed above, on March 16, 2017, we entered into the Purchase Agreement to sell our remaining 80.1% membership interest in PCT to Hitachi America for the Purchase Price.

Financial Information & Liquidity

Liquidity (assuming the Sale Closes in the Second Quarter of 2017) - see Note 3

The Sale may constitute the sale of substantially all of the Company's property and assets under Delaware law, and the Company, is therefore, seeking the approval of the Sale by the Company's stockholders which is scheduled to occur on May 16, 2017. The Company received the Initial Payment in the first quarter of 2017. If the Sale closes, the Company expects to receive the remainder of the Purchase Price (other than the $5.0 million paid into escrow and the milestone payment) in the second quarter of 2017. We believe that the expected cash on hand from the Sale will enable us to fund the development of CLBS03 and other operating expenses for at least the next 12 months following the issuance of our financial statements, as well as to repay our outstanding loan with Oxford Finance LLC in 2017.

We cannot provide assurance as to when the Sale will be completed, or whether it will be completed at all. In addition, if the Purchase Agreement is terminated under certain circumstances, Caladrius will be required to repay the $5.0 million Initial Payment and pay a termination fee of $5.0 million. If such payments are not made within 90 days, Hitachi America's membership interest in PCT will increase from 19.9% to 32.2%. If the Purchase Agreement is terminated under certain other circumstances, Caladrius will be required to return the $5.0 million Initial Payment, and, if it does not do so within 90 days, Hitachi America's membership interest in PCT will increase from 19.9% to 26.0%. Each of these scenarios could have adverse effects on our business, results of operations and the trading price of our common stock.

Liquidity (assuming Sale Does Not Close)

During the three months ended March 31, 2017, the Company incurred a net loss of $9.8 million and used $10.1 million of net cash in operating activities. As of March 31, 2017, the Company's accumulated deficit was $414.1 million. We anticipate requiring additional capital in order to grow our PCT business, to fund the development of CLBS03, to fund other operating expenses, and to make principal and interest payments on our loan with Oxford Finance LLC. To meet our short and long term liquidity needs, we currently expect to use existing cash and cash equivalents balances, our revenue generating activities and a variety of other means, including our common stock purchase agreements with Aspire Capital Fund, LLC ("Aspire") (see Note 12). Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, option exercises, partnerships and/or collaborations and/or sale of assets. In addition, we will continue to seek as appropriate grants for scientific and clinical studies from various governmental agencies and foundations. While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available to us on acceptable terms, if at all. If we are unable to access capital necessary to meet our liquidity needs, we may have to delay or discontinue the development of CLBS03, and/or the expansion of our business or raise funds on terms that we may consider unfavorable.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern for at least the next 12 months following the issuance of these financial statements; however, the above conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverabilty and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2017 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2016 and 2015 included in our 2016 Form 10-K. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining the fair values of goodwill for potential goodwill impairments, useful lives of our long lived assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates as listed below. All intercompany activities have been eliminated in consolidation.



Entity	Percentage of Ownership	Location
Caladrius Biosciences, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America
Athelos Corporation (1)	98.4%	United States of America
PCT, LLC, a Caladrius Company (2)	80.1%	United States of America
NeoStem Family Storage, LLC (2)	80.1%	United States of America
PCT Allendale, LLC (2)	80.1%	United States of America

_________________________________________________________________

(1) As of March 31, 2017, Becton Dickinson's ownership interest was 1.6%.

(2) As of March 31, 2017, Hitachi's ownership interest was 19.9% (see Note 3).

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2016 Form 10-K. There were no changes to these policies during the three months ended March 31, 2017.

Concentration of Risks

We are subject to credit risk from our portfolio of cash and cash equivalents. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.

We are also subject to credit risk from our accounts receivable related to our services. The majority of our trade accounts receivable arises from services in the United States.

For the three months ended March 31, 2017, the three largest customers represented 59% of total revenues recognized, the largest of which was 23%. As of March 31, 2017, three customers represented 66% of our accounts receivable, the largest of which was 32%.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Goodwill

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives.

The Company reviews goodwill at least annually, or at the time a triggering event is identified for possible impairment. Goodwill is reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill each year on December 31. The Company reviews the carrying value of goodwill utilizing an income approach model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with its accounting policy, the Company tested goodwill for impairment as of December 31, 2016 and concluded there was no goodwill impairment.

Long-Lived Assets

Long-lived assets consist of customer lists, manufacturing technology, tradenames, patents and rights, as well as property, plant and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No triggering events were noted in the quarters ended March 31, 2017 or March 31, 2016 that would require interim impairment assessment.

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collection is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.

Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance.

Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when contractual terms have been met.

Some client agreements include multiple elements, comprised of cell process development and cell manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended March 31, 2017 and 2016, clinical services reimbursements were $1.7 million and $1.3 million, respectively.

Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

License Fees: PCT and Hitachi Chemical also entered into an exclusive license agreement for Asia pursuant to which PCT received $5.6 million from Hitachi Chemical in 2016. PCT licensed to Hitachi Chemical certain cell therapy technology and know-how (including an exclusive license to use the PCT brand in Asia) and agreed to provide Hitachi Chemical with certain training and support. As additional consideration, Hitachi Chemical will pay PCT royalties on contract revenue generated in Asia for a minimum of ten years. The initial term of the Hitachi License Agreement is ten years and may be automatically extended for successive additional two year terms. The Company recognizes the payments as revenue on a straight-line basis over the initial ten-year term. For the three months ended March 31, 2017 and 2016, the Company recognized $0.14 million and $0.02 million of license fee revenue, respectively. As of March 31, 2017, $0.6 million of Hitachi license fees were included in unearned revenue, and $4.4 million was included in unearned revenue - long-term.

Recently Issued Accounting Pronouncement

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09) and has subsequently issued a number of amendments to ASU 2014-09. The new standard, as amended, provides a single comprehensive model to be used in the accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific guidance. The standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 includes provisions within a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard will be effective for us beginning January 1, 2018 and permits two methods of adoption: the full retrospective method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements and has not yet selected the transition method. The Company anticipates assigning internal resources to assist with the evaluation and implementation of the new standard, and will continue to provide updates during 2017.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The guidance will be applied prospectively, retrospectively, or by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted, dependent upon the specific amendment that is adopted within the ASU. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

Collaboration and License Agreement

3 Months Ended

Mar. 31, 2017

Business Combinations [Abstract]

Collaboration and License Agreement

March 2016 Hitachi Transaction

On March 11, 2016, PCT entered into a global collaboration with Hitachi. This collaboration consists of an equity investment in and a license agreement with PCT.

Under the equity investment agreement, Hitachi purchased a 19.9% membership interest in PCT for $19.4 million of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT to be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes. Caladrius remains the majority shareholder retaining an 80.1% ownership interest.

PCT and Hitachi also entered into an exclusive license agreement for the acceleration of the creation of a global commercial cell therapy development and manufacturing expertise in Asia pursuant to which PCT received $5.6 million from Hitachi in 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi Chemical with certain training and support. As additional consideration, Hitachi Chemical will pay PCT royalties on contract revenue generated in Asia for a minimum of ten years.

Lastly, as part of the transaction, PCT and Hitachi Chemical agreed to explore the possibility of pursuing a collaboration in cell therapy contract development and manufacturing in Europe.

2017 Hitachi Transaction

On March 16, 2017, Caladrius entered into the Purchase Agreement, by and among Caladrius, PCT and Hitachi America, pursuant to which Hitachi America has agreed to acquire the 80.1% membership interest in PCT that it does not already own from Caladrius for $75.0 million in cash, subject to potential adjustment, based on PCT’s cash and outstanding indebtedness as of the closing of the transaction, a potential future milestone payment of $5.0 million based on PCT's revenue in 2017-2018 and certain transaction expenses. Pursuant to the terms of the Purchase Agreement, Hitachi America paid Caladrius $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction, expected to occur on May 16, 2017, and other closing conditions included in the Purchase Agreement. Upon closing of the Sale this $5.0 million advance payment, which is included in the liability section of the balance sheet as an Advance Payment Received From Potential PCT Sale, will be applied toward the total $75.0 million purchase consideration. At the closing of the Sale, Caladrius will receive $65.0 million, with $5.0 million of the purchase consideration to be deposited into an escrow account to cover potential indemnification claims against Caladrius.

As part of the Purchase Price, Hitachi will pay Caladrius the $5.0 million Milestone Payment if PCT achieves $125.0 million in cumulative revenue (excluding clinical service reimbursables) for the period from January 1, 2017 through December 31, 2018. For purposes of the Milestone Payment, cumulative revenue will be calculated based on PCT’s revenue from all customers (including Caladrius and its subsidiaries) in accordance with the financial accounting and reporting standards set forth in the statements and pronouncements of the FASB, consistently applied.

Generally, in the event of a Change in Control of Caladrius (as defined in the 2009 Plan and the 2015 Equity Plan, and, together with the 2009 Plan, the “Equity Compensation Plans”), (a) all outstanding options and stock appreciation rights of each participant granted prior to the change in control shall be fully vested and immediately exercisable in their entirety, and (b) all unvested stock awards, restricted stock units, restricted stock, performance-based awards, and other awards shall become fully vested, including without limitation, the following: (i) the restrictions to which any shares of restricted stock granted prior to the change in control are subject shall lapse as if the applicable restriction period had ended upon such change in control, and (ii) the conditions required for vesting of any unvested performance-based awards shall be deemed to be satisfied upon such change in control. The approval of the Sale by our stockholders will result in a Change in Control under our Equity Compensation Plans. Accordingly, all outstanding unvested equity awards will be accelerated if the Sale is approved by our stockholders.

Concurrent with the signing of the Purchase Agreement, on March 16, 2017, Caladrius entered into a Retention and Incentive Agreement with Robert A. Preti, a former Caladrius director and a co-founder and the President of PCT, (the “Retention Agreement”). The Retention Agreement supersedes all prior agreements and understandings between Dr. Preti and Caladrius regarding the subject matter of the Retention Agreement. Among other things, the Retention Agreement provides for:


•	Simultaneously with the Closing, Caladrius will pay to Dr. Preti $1.375 million (the “First Retention Payment”).

•

As an incentive to remain employed with PCT and to use commercially reasonable efforts to cause PCT to maximize its overall performance and in particular to achieve the Milestone (but not contingent upon achieving the Milestone), Dr. Preti will receive a lump-sum cash retention and incentive payment equal to $1.375 million for the period from Closing until the date one year after the date of the Closing (the “Anniversary Date”), subject to Dr. Preti’s continued employment with PCT through the Anniversary Date (the “Second Retention Payment”).


•	Dr. Preti will be entitled to 5% of the Milestone Payment if it is successfully earned.

All payments are contingent on Closing of the Sale.

Available-for-Sale-Securities

3 Months Ended

Mar. 31, 2017

Available-for-sale Securities [Abstract]

Cash, Cash Equivalents, and Marketable Securities [Text Block]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	March 31, 2017								December 31, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	1,430.4	$	—	$	—	$	1,430.4	$	4,426.8	$	—	$	—	$	4,426.8
Municipal debt securities	—		—		—		—		—		—		—		—
Total	$	1,430.4	$	—	$	—	$	1,430.4	$	4,426.8	$	—	$	—	$	4,426.8

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	1,430.4	$	4,426.8
Total	$	1,430.4	$	4,426.8

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	March 31, 2017
	Amortized Cost		Estimated Fair Value
Less than one year	$	1,430.4	$	1,430.4
Greater than one year	—		—
Total	$	1,430.4	$	1,430.4

Deferred Costs	3 Months Ended
Deferred Costs	Mar. 31, 2017
Inventories [Abstract]
Deferred Costs	Deferred Costs Deferred costs, representing work in process for costs incurred on process development contracts that have not been completed, were $3.5 million and $3.6 million as of March 31, 2017 and December 31, 2016, respectively. The Company also has deferred revenue of approximately $4.3 million and $4.0 million of advance billings received as of March 31, 2017 and December 31, 2016, respectively, related to these contracts.

Loss Per Share

3 Months Ended

Mar. 31, 2017

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the three months ended March 31, 2017 and 2016, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive. At March 31, 2017 and 2016, the Company excluded the following potentially dilutive securities:



	March 31
	2017	2016
Stock Options	1,133,459	722,708
Warrants	336,062	460,547
Restricted Shares	132,726	53,935

Fair Value Measurements

3 Months Ended

Mar. 31, 2017

Fair Value Measurements [Abstract]

Fair Value Disclosures [Text Block]

Fair Value Measurements

The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company had no financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2017, and December 31, 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2017

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The Company's goodwill was $7.0 million as of March 31, 2017 and December 31, 2016. All goodwill resides in the PCT reporting unit.

The Company's intangible assets and related accumulated amortization as of March 31, 2017 and December 31, 2016 consisted of the following (in thousands):



		March 31, 2017							December 31, 2016
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(620.1	)	$	379.9	$	1,000.0	$	(595.1	)	$	404.9
Manufacturing technology	10 years	3,900.0		(2,418.4		)	1,481.6		3,900.0		(2,320.9		)	1,579.1
Tradename	10 years	800.0		(496.1		)	303.9		800.0		(476.1		)	323.9
Total intangible assets		$	5,700.0	$	(3,534.6	)	$	2,165.4	$	5,700.0	$	(3,392.1	)	$	2,307.9

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended March 31,
	2017		2016
Cost of revenue	$	78.6	$	79.6
Research and development	18.9		17.9
Selling, general and administrative	45.0		45.0
Total	$	142.5	$	142.5

Estimated intangible amortization expense for the succeeding five years is as follows (in thousands):



2017	$	427.5
2018	570.0
2019	570.0
2020	570.0
Thereafter	27.9
Total	$	2,165.4

Accrued Liabilities

3 Months Ended

Mar. 31, 2017

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

Accrued liabilities as of March 31, 2017 and December 31, 2016 were as follows (in thousands):



	March 31, 2017		December 31, 2016
Salaries, employee benefits and related taxes	$	2,759.4	$	4,209.7
Professional fees	730.0		224.5
Other	1,572.4		1,628.4
Total	$	5,061.8	$	6,062.6

Debt

3 Months Ended

Mar. 31, 2017

Debt [Abstract]

Debt Disclosure [Text Block]

Debt

Notes Payable

As of March 31, 2017 and December 31, 2016, the Company had notes payable of approximately $1.2 million and $1.1 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.

Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender disbursed $15.0 million (the “Loan”). The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Loan using the effective interest rate method.

On March 11, 2016, upon the sale of a 19.9% membership interest in PCT to Hitachi America and our entry into a technology license agreement with Hitachi America (collectively, the “March 2016 Hitachi Transaction”), the Company and the Lender entered into an amendment to the Loan and Security Agreement whereby (i) the Company paid $7.0 million to Lender, comprising principal, interest and early termination fees, (ii) the Company's subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Lender's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance was extended until January 1, 2017, and (v) in the event the Company received gross proceeds from the sale or issuance of any equity securities or subordinated debt, or any partnership, licenses, collaboration, dividend, grant or asset sale through March 31, 2017, 20% of such proceeds will be paid to Lender, up to a $3.0 million maximum as additional partial repayment of Loan. On September 14, 2016, concurrent with the Company's September 2016 Registered Direct Offering and Concurrent Private Placement (see Note 12), the Company repaid $3.0 million of such proceeds to the Lender. The outstanding balance was approximately $4.9 million and $5.7 million at March 31, 2017 and December 31, 2016, respectively, of which $3.2 million is payable within twelve months as of March 31, 2017.

The Company was making interest-only payments on the outstanding amount of the Loan on a monthly basis at a rate of 8.50% per annum through December 31, 2016. Commencing on January 1, 2017, the Company began making 21 consecutive monthly payments of principal and interest. The Loan matures on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Loan. The final payment fee will be amortized to interest expense throughout the life of the Loan using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with the Loan.

Under the Loan and Security Agreement, the Lender holds a security interest ("Lenders' Security Interest") in all of the Company’s property, excluding the security interests in any and all assets of the Removed Borrowers, and excluding intellectual property and certain other assets and exemptions. The Lender also holds a security interest in the shares owned by the Company in the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of Lenders' Security Interest and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated to the Loan and Security Agreement. As of March 31, 2017, the Company was in compliance with all covenants under the Loan and Security Agreement.

Estimated future principal payments due under the Loan and Security Agreement are as follows:



Years Ending December 31,	(in thousands)
2017	$	2,369.5
2018	2,524.9
Total	$	4,894.4

During the three months ended March 31, 2017 and March 31, 2016, the Company recognized $0.1 million and $0.3 million of interest expense, respectively, related to the Loan and Security Agreement.

Redeemable Securities	3 Months Ended
Redeemable Securities	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Redeemable Securities [Text Block]	Redeemable Securities Under the Hitachi Transaction (see Note 3), Hitachi may, at any time following the tenth anniversary of the March 2016 Hitachi Transaction closing date on March 11, 2016, have the right on one occasion to require Caladrius or PCT to purchase all or some of the equity securities in PCT then held by Hitachi ("Hitachi Put Right") for an amount equal to the lower of (i) the fair market value of the Hitachi equity holdings and (ii) the original purchase price paid of $19.4 million on March 11, 2016 for its 19.9% ownership interest, plus interest at a rate of 2.0% per annum compounded annually; provided, however, that if Hitachi ownership interests increases subsequent to its initial ownership interest, and it offers to sell its equity holdings in excess of 21% of PCT’s outstanding equity securities, then the Company shall be required to purchase all such equity holdings of Hitachi but in no event shall the aggregate purchase price of such Hitachi equity holdings exceed $20.5 million plus interest at the rate of 2.0% per annum compounded annually. Since Hitachi has the right to deliver the equity interests in PCT it holds in exchange for cash from Caladrius or PCT, the initial $19.4 million value of the non-controlling interest is considered redeemable equity, requiring it to be treated as mezzanine equity. Redeemable non-controlling interest is required to be initially measured at the initial carrying amount. If the non-controlling interest is not currently redeemable and also not probable of becoming redeemable (e.g., it is not probable a contingency that triggers redemption will be met), the non-controlling interest should be classified in mezzanine equity.

Shareholders' Equity

3 Months Ended

Mar. 31, 2017

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Shareholders' Equity

Reverse Stock Split

On July 28, 2016, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on June 22, 2016 and unanimously approved by the Company’s board of directors on July 22, 2016. The Reverse Stock Split became effective on July 27, 2016 at 5:00pm and the common stock of the Company began trading on The NASDAQ Capital Market on a post-split basis at the open of business on July 28, 2016. As of July 28, 2016, every ten shares of the Company’s issued and outstanding common stock were combined into one share of its common stock, except to the extent that the Reverse Stock Split resulted in any of the Company’s stockholders owning a fractional share, which was rounded up to the next highest whole share. In connection with the Reverse Stock Split, there was no change in the nominal par value per share of $0.001.

All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “Additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.

Equity Issuances

September 2016 Registered Direct Offering and Concurrent Private Placement

On September 14, 2016, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company issued and sold to the Purchaser, in a registered direct offering, an aggregate of 847,458 shares of the Company’s common stock at a purchase price of $4.72 per share. The gross proceeds to the Company from the registered direct offering of the shares of common stock were $4.0 million.

In concurrent private placements, on September 14, 2016, the Company entered into Securities Purchase Agreements (each a “Private Placement Purchase Agreement” and, collectively, the “Private Placement Purchase Agreements”) with certain accredited investors (the “Investors”) with whom it had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by the Company of an aggregate of 4,449,153 shares of Common Stock, at a purchase price of $4.72 per share. The investments will be placed in two tranches: (i) $12.6 million upon an initial closing (the “Initial Closing”), and (ii) $8.4 million, subject to certain conditions, including the enrollment of 70 subjects in the Company’s Phase 2 CLBS03 clinical trial, in a second closing (the “Second Closing”). As of March 31, 2017, $6.0 million of the Initial Closing tranche had not been received from a single investor, who was in breach of his obligations under the Private Placement Purchase Agreement. This investor had also committed to fund $4.0 million in the Second Closing. As a result, the Company has terminated the Private Placement Purchase Agreement with this investor in the first quarter of 2017. On March 22, 2017, Sanford Health agreed to waive the conditions for the Second Closing and purchased 423,729 shares of common stock resulting in gross proceeds to the Company of $2.0 million.

Aspire Purchase Agreements

In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 1.1 million shares, unless stockholder approval is obtained or certain minimum sale price levels are reached) of the Company's common stock over a 24-month term. As consideration for entering into the Purchase Agreement, the Company issued 84,270 shares of its common stock to Aspire Capital. During the three months ended March 31, 2017, the Company issued 210,506 shares of common stock under the Purchase Agreement for gross proceeds of $1.2 million. Overall, as of March 31, 2017, the Company has issued 319,776 shares under the Purchase Agreement for gross proceeds of $1.5 million.

Under the Purchase Agreement, at the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price, trading volume and conditions, including NASDAQ's trading requirements, are met. The purchase price for the shares of common stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements. We have filed a registration statement with the SEC and a related prospectus supplement that covers the offering of shares of our common stock subject to the Purchase Agreement, and therefore can initiate sales to Aspire Capital at any time, subject to the limitation discussed above.

We are party to one other existing agreement with Aspire Capital (the "May 2015 Purchase Agreement"). The registration statement we previously filed with the SEC to cover offerings of shares of our common stock subject to the May 2015 Purchase Agreement has expired, and we have not, and currently have no intention to include such shares in a registration statement filed with the SEC. Unless and until we include such shares in a registration statement filed with the SEC, we are unable to initiate sales to Aspire under the May 2015 Purchase Agreement. Under the May 2015 Purchase Agreement, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares. As consideration for entering into the May 2015 Purchase Agreement, the Company issued 36,484 shares of its common stock to Aspire Capital. The Company has not issued any additional shares under the May 2015 Purchase Agreement.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2017, as adjusted for the Reverse Stock Split:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016	952,790		$	39.90	7.60	$	—	388,062		$	76.50	1.24	$	—

Changes during the period:
Granted	209,418		3.60					—		—
Exercised	—		—					—		—
Forfeited	(6,294	)	8.40					—		—
Expired	(22,455	)	43.20					(52,000	)	51.30
Outstanding at March 31, 2017	1,133,459		$	33.30	7.80	$	386.5	336,062		$	80.40	1.15	$	—
Vested at March 31, 2017 or expected to vest in the future	1,103,988		$	34.00	7.76	$	357.7	336,062		$	80.40	1.15	$	—
Vested at March 31, 2017	821,156		$	43.10	7.23	$	133.6	336,062		$	80.40	1.15	$	—

Restricted Stock

During the three months ended March 31, 2017 and 2016, the Company issued restricted stock for services as follows (in thousands, except share data):



	Three Months Ended March 31,
	2017		2016
Number of restricted stock issued	132,726		98,383
Value of restricted stock issued	$	469.9	$	562.8

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Share-Based Compensation

3 Months Ended

Mar. 31, 2017

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2017 and 2016 (in thousands):



	Three Months Ended March 31,
	2017		2016
Cost of goods sold	$	46.8	$	124.3
Research and development	52.5		92.3
Selling, general and administrative	433.9		634.6
Total share-based compensation expense	$	533.2	$	851.2

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at March 31, 2017 were as follows (in thousands):



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	1,381.2	$	651.5
Expected weighted-average period in years of compensation cost to be recognized	1.85		2.08

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2017 and 2016 were as follows, as adjusted for the Reverse Stock Split (in thousands):



	Stock Options
	Three Months Ended March 31,
	2017		2016
Total fair value of shares vested	$	507.1	$	994.1
Weighted average estimated fair value of shares granted	$	2.34	$	4.10

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Research Funding	3 Months Ended
Research Funding	Mar. 31, 2017
Research Funding [Abstract]
Research Funding	Research Funding California Institute of Regenerative Medicine Grant Award On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017 (see Note 18).

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2017
Income Taxes [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes As of December 31, 2016, the Company had approximately $232.7 million of federal net operating loss carryforwards ("NOLs") available to offset future taxable income expiring from 2027 through 2036. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2036. In assessing the ability to realize deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as the Company's ability to generate taxable income remains uncertain at this time. Deferred tax liabilities were $1.1 million and $1.1 million as of March 31, 2017 and December 31, 2016, respectively, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011. The taxable temporary differences, which are tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the deferred tax provision in each period. The deferred tax liability will only reverse when the indefinite-lived asset is sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset. The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense. As of March 31, 2017, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year. The Company completed the audit of its federal tax returns for the years 2012 and 2013 during the fourth quarter of 2016. The audit resulted in an adjustment to the Company's NOL carryforward. For years prior to 2014 the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing. The Company ceased doing business in China in 2012. After 2012, the Company had no foreign tax filing obligations. The foreign returns filed for 2012 and prior are subject to examination for five years.

Segment Information

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Information

In connection with the contemplated sale of the remaining interest in PCT to Hitachi Chemical, we reorganized our financial reporting into two distinct reportable operating segments.


•	The R&D Segment which develops early-stage cellular therapeutic candidates to treat certain diseases with the intention of partnering these candidates post proof-of-concept in humans.


•	The PCT Segment which provides development and manufacturing services to the cell and cell-based gene therapy industry.

Each operating segment is individually reviewed and evaluated by our Chief Operating Decision Maker (CODM), who allocates resources and assesses performance of each segment individually. The CODM evaluates segment performance primarily based on loss from operations. The Company's Chief Executive Officer has been identified as the CODM.

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax benefit (expense), and assets for the three months ended March 31, 2017 and 2016 ($ in thousands):



	Three Months Ended March 31, 2017									Three Months Ended March 31, 2016
	R&D Segment			PCT Segment			Total			R&D Segment			PCT Segment			Total
Net revenues	$	—		$	7,922.7		$	7,922.7		$	—		$	7,489.5		$	7,489.5
Cost of revenues	—			8,042.3			8,042.3			—			6,228.3			6,228.3
Operating loss	(7,736.6		)	(1,795.1		)	(9,531.7		)	(10,876.3		)	(197.0		)	(11,073.3		)
Depreciation and amortization	98.9			556.4			655.3			153.1			584.1			737.2
Interest expense	158.9			8.8			167.7			897.2			29.6			926.8
Provision for income taxes	—			49.5			49.5			—			53.4			53.4

Total assets	$	13,049.0		$	35,479.5		$	48,528.4		$	21,883.7		$	41,301.2		$	63,184.9

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

We lease facilities under various operating lease agreements in Basking Ridge, NJ, New York, NY, Irvine, CA , and Mountain View, CA, of which certain have escalation clauses and renewal options. We also lease equipment under certain noncancelable operating leases. Our leases expire from time to time through 2021.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2017 are as follows (in thousands):



Years ended	Operating Leases
2017	$	1,683.1
2018	1,723.5
2019	1,332.7
2020	792.1
2021 and thereafter	168.1
Total minimum lease payments	$	5,699.5

Expense incurred under operating leases was approximately $0.5 million and $0.5 million for the three months ended March 31, 2017 and 2016, respectively.

Contingencies

We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: T-Rex Study) to evaluate the safety and efficacy of the Company’s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment commenced in the first quarter of 2016. We were initially responsible for the supply of all study drug to the first 19 enrolled patients while Sanford assumed all patient and clinical site costs for subjects enrolled in their two centers as well as the expense associated with general clinical monitoring services. For the remaining 92 patients in the study, we will continue to be responsible for the supply of all study drug and the costs of study enrollment for sites outside of the Sanford centers.

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

Under the Hitachi Transaction, Hitachi may require the Company to purchase all of its ownership in PCT if a Change of Control has occurred (as defined in the Amended and Restated Operating Agreement of PCT), and if such Change of Control can reasonably be expected to have a material adverse effect on PCT’s ability to conduct its business in the ordinary course consistent with its past practice and its then current annual budget, at a price to be agreed upon by mutual agreement, provided, however, if mutual agreement is not obtained, the price will be determined by independent valuation firms.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events California Institute of Regenerative Medicine Grant Award On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017 (see Note 14).

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies [Abstract]

Concentration of Risks

Share-based Compensation

Share-Based Compensation

Goodwill and Intangible Assets

Goodwill

Long-Lived Assets

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collection is probable.

Recently Issued Accounting Pronouncement

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

The Business (Tables)

3 Months Ended

Mar. 31, 2017

The Business [Abstract]

Summary of Principles of Consolidation



Entity	Percentage of Ownership	Location
Caladrius Biosciences, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America
Athelos Corporation (1)	98.4%	United States of America
PCT, LLC, a Caladrius Company (2)	80.1%	United States of America
NeoStem Family Storage, LLC (2)	80.1%	United States of America
PCT Allendale, LLC (2)	80.1%	United States of America

_________________________________________________________________

(1) As of March 31, 2017, Becton Dickinson's ownership interest was 1.6%.

(2) As of March 31, 2017, Hitachi's ownership interest was 19.9% (see Note 3).

Available-for-Sale-Securities (Tables)

3 Months Ended

Mar. 31, 2017

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	March 31, 2017								December 31, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	1,430.4	$	—	$	—	$	1,430.4	$	4,426.8	$	—	$	—	$	4,426.8
Municipal debt securities	—		—		—		—		—		—		—		—
Total	$	1,430.4	$	—	$	—	$	1,430.4	$	4,426.8	$	—	$	—	$	4,426.8

Marketable Securities [Table Text Block]



	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	1,430.4	$	4,426.8
Total	$	1,430.4	$	4,426.8

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	March 31, 2017
	Amortized Cost		Estimated Fair Value
Less than one year	$	1,430.4	$	1,430.4
Greater than one year	—		—
Total	$	1,430.4	$	1,430.4

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2017

Loss Per Share [Abstract]

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At March 31, 2017 and 2016, the Company excluded the following potentially dilutive securities:



	March 31
	2017	2016
Stock Options	1,133,459	722,708
Warrants	336,062	460,547
Restricted Shares	132,726	53,935

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2017

Goodwill and Other Intangible Assets [Abstract]

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

The Company's intangible assets and related accumulated amortization as of March 31, 2017 and December 31, 2016 consisted of the following (in thousands):



		March 31, 2017							December 31, 2016
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(620.1	)	$	379.9	$	1,000.0	$	(595.1	)	$	404.9
Manufacturing technology	10 years	3,900.0		(2,418.4		)	1,481.6		3,900.0		(2,320.9		)	1,579.1
Tradename	10 years	800.0		(496.1		)	303.9		800.0		(476.1		)	323.9
Total intangible assets		$	5,700.0	$	(3,534.6	)	$	2,165.4	$	5,700.0	$	(3,392.1	)	$	2,307.9

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended March 31,
	2017		2016
Cost of revenue	$	78.6	$	79.6
Research and development	18.9		17.9
Selling, general and administrative	45.0		45.0
Total	$	142.5	$	142.5

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense for the succeeding five years is as follows (in thousands):



2017	$	427.5
2018	570.0
2019	570.0
2020	570.0
Thereafter	27.9
Total	$	2,165.4

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2017

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities as of March 31, 2017 and December 31, 2016 were as follows (in thousands):



	March 31, 2017		December 31, 2016
Salaries, employee benefits and related taxes	$	2,759.4	$	4,209.7
Professional fees	730.0		224.5
Other	1,572.4		1,628.4
Total	$	5,061.8	$	6,062.6

Debt Long term debt (Tables)

3 Months Ended

Mar. 31, 2017

Long-term Debt, Unclassified [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]

Estimated future principal payments due under the Loan and Security Agreement are as follows:



Years Ending December 31,	(in thousands)
2017	$	2,369.5
2018	2,524.9
Total	$	4,894.4

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2017

Shareholders’ Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2017, as adjusted for the Reverse Stock Split:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016	952,790		$	39.90	7.60	$	—	388,062		$	76.50	1.24	$	—

Changes during the period:
Granted	209,418		3.60					—		—
Exercised	—		—					—		—
Forfeited	(6,294	)	8.40					—		—
Expired	(22,455	)	43.20					(52,000	)	51.30
Outstanding at March 31, 2017	1,133,459		$	33.30	7.80	$	386.5	336,062		$	80.40	1.15	$	—
Vested at March 31, 2017 or expected to vest in the future	1,103,988		$	34.00	7.76	$	357.7	336,062		$	80.40	1.15	$	—
Vested at March 31, 2017	821,156		$	43.10	7.23	$	133.6	336,062		$	80.40	1.15	$	—

Restricted Stock [Table Text Block]

During the three months ended March 31, 2017 and 2016, the Company issued restricted stock for services as follows (in thousands, except share data):



	Three Months Ended March 31,
	2017		2016
Number of restricted stock issued	132,726		98,383
Value of restricted stock issued	$	469.9	$	562.8

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2017

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2017 and 2016 (in thousands):



	Three Months Ended March 31,
	2017		2016
Cost of goods sold	$	46.8	$	124.3
Research and development	52.5		92.3
Selling, general and administrative	433.9		634.6
Total share-based compensation expense	$	533.2	$	851.2

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	1,381.2	$	651.5
Expected weighted-average period in years of compensation cost to be recognized	1.85		2.08

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]



	Stock Options
	Three Months Ended March 31,
	2017		2016
Total fair value of shares vested	$	507.1	$	994.1
Weighted average estimated fair value of shares granted	$	2.34	$	4.10

Segment Information (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Schedule of Segment Reporting Information



	Three Months Ended March 31, 2017									Three Months Ended March 31, 2016
	R&D Segment			PCT Segment			Total			R&D Segment			PCT Segment			Total
Net revenues	$	—		$	7,922.7		$	7,922.7		$	—		$	7,489.5		$	7,489.5
Cost of revenues	—			8,042.3			8,042.3			—			6,228.3			6,228.3
Operating loss	(7,736.6		)	(1,795.1		)	(9,531.7		)	(10,876.3		)	(197.0		)	(11,073.3		)
Depreciation and amortization	98.9			556.4			655.3			153.1			584.1			737.2
Interest expense	158.9			8.8			167.7			897.2			29.6			926.8
Provision for income taxes	—			49.5			49.5			—			53.4			53.4

Total assets	$	13,049.0		$	35,479.5		$	48,528.4		$	21,883.7		$	41,301.2		$	63,184.9

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2017 are as follows (in thousands):



Years ended	Operating Leases
2017	$	1,683.1
2018	1,723.5
2019	1,332.7
2020	792.1
2021 and thereafter	168.1
Total minimum lease payments	$	5,699.5

The Business Proposed Sale of Remaining Interest in PCT to Hitachi America (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 16, 2017	Mar. 31, 2017	Mar. 11, 2016
Subsidiary, Sale of Stock [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%		80.10%
Hitachi Chemical Co., LTD [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds From Licensing Agreements, Initial Payment	$ 5.0	$ 5.0
Cumulative Revenue Threshold for Receiving Milestone Payment		125.0
PCT Allendale, LLC [Member] \| Hitachi Chemical Co., LTD [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds From Licensing Agreements	75.0	$ 75.0
Cumulative Revenue Threshold for Receiving Milestone Payment	$ 125.0

The Business CLBS03 (Details) $ in Millions	12 Months Ended
The Business CLBS03 (Details) $ in Millions	Dec. 31, 2015 cohort	May 04, 2017 USD ($)	Feb. 23, 2017 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Interim Efficacy Analysis, Percentage Threshold	50.00%
Interim Efficacy Analysis, Follow-up Milestone Period	6 years
Grants Receivable			$ 12.2
The Sanford Project: T-Rex Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of Cohorts \| cohort	2
Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grants Receivable, Current		$ 5.7

The Business Cell Therapy Development and Manufacturing (Details)	3 Months Ended
	Mar. 31, 2017 client product filing	Mar. 16, 2017	Mar. 11, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Equity Method Investment, Ownership Percentage			19.90%
Subsidiary, Ownership Interest by Parent		80.10%	80.10%
PCT Allendale, LLC [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number Of Clients \| client	100
Number Of Products Produced \| product	20,000
PCT Allendale, LLC [Member] \| United States And European Union [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number Of Supported Regulatory Filings \| filing	50

The Business Financial Information & Liquidity (Details) - USD ($)		3 Months Ended
	Mar. 16, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Mar. 11, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds From Licensing Agreements, Milestone Payments		$ (5,000,000)	$ 0
Equity Method Investment, Ownership Percentage					19.90%
Equity Method Investment, Ownership Percentage, If Initial Payment and Termination Fee Not Paid		32.20%
Equity Method Investment, Ownership Percentage, If Agreement Is Terminated		26.00%
Net loss		$ (9,793,324)	(12,047,796)
Net cash used in operating activities		(10,087,908)	$ (8,028,298)
Accumulated deficit		(414,148,636)		$ (404,788,809)
Hitachi Chemical Co., LTD [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds From Licensing Agreements, Milestone Payments	$ 5,000,000	5,000,000
Proceeds From Licensing Agreements, Initial Payment	$ 5,000,000	5,000,000
Loss on Contract Termination		$ 5,000,000
Equity Method Investment, Ownership Percentage					21.00%

The Business Principal of consolidation (Details)	Mar. 31, 2017	Mar. 16, 2017	Mar. 11, 2016
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent		80.10%	80.10%
NeoStem, Inc. [Member]
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Oncology [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Athelos Corporation [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	98.40%
PCT Allendale, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%
Becton Dickson [Member]
Schedule of Subisidiary [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	1.60%
Hitachi Chemical Co., LTD [Member]
Schedule of Subisidiary [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	19.90%

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Mar. 11, 2016
Concentration Risk [Line Items]
Goodwill impairment				$ 0
Clinical Services Reimbursement	$ 1,700,000	$ 1,300,000
Revene Recognition Period for Cryoperservation Process					24 hours
Unearned revenues, current	$ 5,364,662			$ 5,098,193
Customer Concentration Risk [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	59.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	66.00%
Customer One [Member] \| Customer Concentration Risk [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	23.00%
Customer One [Member] \| Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	32.00%
PCT Allendale, LLC [Member]
Concentration Risk [Line Items]
Contract Receivable						$ 5,600,000
Licenses Revenue	$ 140,000	$ 20,000
Unearned revenues, current	600,000
Deferred Revenue, Noncurrent	$ 4,400,000
PCT Allendale, LLC [Member]
Concentration Risk [Line Items]
Length of Extension Contract for Royalty Payments from Revenue Generated in Asia			2 years
Minimum [Member] \| PCT Allendale, LLC [Member]
Concentration Risk [Line Items]
Length of Contract for Royalty Payments from Revenue Generated in Asia			10 years

Collaboration and License Agreement (Details) - USD ($)		3 Months Ended			9 Months Ended
Collaboration and License Agreement (Details) - USD ($)	Mar. 16, 2017	Jun. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Sep. 30, 2016	Mar. 11, 2016
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage						19.90%
Subsidiary, Ownership Interest by Parent	80.10%					80.10%
Proceeds From Licensing Agreements, Milestone Payments			$ (5,000,000)	$ 0
Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage						21.00%
Recorded Unconditional Purchase Obligation				$ 20,500,000		$ 19,400,000
Unrecorded Unconditional Purchase Obligation, Maximum Quantity						15,000,000
Proceeds From Licensing Agreements, Initial Payment	$ 5,000,000		5,000,000
Proceeds From Licensing Agreements, Milestone Payments	5,000,000		5,000,000
Cumulative Revenue Threshold for Receiving Milestone Payment			125,000,000
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Contract Receivable						$ 5,600,000
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Purchase Obligation						$ 4,400,000
PCT Allendale, LLC [Member] \| Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Proceeds From Licensing Agreements	75,000,000		$ 75,000,000
Cumulative Revenue Threshold for Receiving Milestone Payment	$ 125,000,000
Minimum [Member] \| PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Length of Contract for Royalty Payments from Revenue Generated in Asia					10 years
Scenario, Forecast [Member] \| Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Proceeds From Licensing Agreements		$ 5,000,000
Proceeds From Licensing Agreements, Closing Payments		65,000,000
Director [Member] \| Scenario, Forecast [Member] \| Robert A. Preti [Member]
Business Acquisition [Line Items]
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment		1,375,000
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment		$ 1,375,000
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment		5.00%

Available-for-Sale-Securities Schedule of Available-for-sale Securites Reconciliation (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 1,430,400	$ 4,426,800
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	1,430,400	4,426,800
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	1,430,400	4,426,800
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	1,430,400	4,426,800
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	0	0
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	$ 0	$ 0

Available-for-Sale-Securities Classification of the available-for-sale securities (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2015
Available-for-sale Securities [Abstract]
Cash	$ 1,430,400	$ 4,426,800
Total	$ 1,430,400	$ 4,426,800

Available-for-Sale-Securities Available-for-sale Securities by Contractual Maturity (Details)	Mar. 31, 2017 USD ($)
Available-for-sale Securities [Abstract]
Amortized Cost	$ 1,430,400
Available-for-sale Securities, Debt Maturities, Remainder of Fiscal Year, Amortized Cost Basis	1,430,400
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis	0
Available-for-sale Securities, Noncurrent	0
Estimated Fair Value	$ 1,430,400

- Definition

Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

+ References + Details

Deferred Costs (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Schedule of Inventory [Line Items]
Deferred costs	$ 3,538,641	$ 3,582,298
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 4,300,000	$ 4,000,000

Loss Per Share (Details) - shares	3 Months Ended
Loss Per Share (Details) - shares	Mar. 31, 2017	Mar. 31, 2016
Warrants
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	336,062	460,547
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	1,133,459	722,708
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	132,726	53,935

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 5,700,000	$ 5,700,000
Finite-Lived Intangible Assets, Accumulated Amortization	(3,534,600)	(3,392,100)
Finite-Lived Intangible Assets, Future Amortization Expense	2,165,400	2,307,900
Customer Lists [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(620,100)	(595,100)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 379,900	404,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,418,400)	(2,320,900)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 1,481,600	1,579,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(496,100)	(476,100)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 303,900	$ 323,900
Finite-Lived Intangible Assets, Useful Life	10 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 142,500	$ 142,500
Cost of revenue
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	78,600	79,600
Research and development
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	18,900	17,900
Selling, general and administrative
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 45,000	$ 45,000

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Goodwill [Abstract]
Goodwill	$ 7,000,000	$ 7,000,000
Future Amortization Expense, Year Two	427,500
Future Amortization Expense, Year Three	570,000
Future Amortization Expense, Year Four	570,000
Future, Amortization Expense, Year Five	570,000
Thereafter	27,900
Finite-Lived Intangible Assets, Future Amortization Expense	$ 2,165,400	$ 2,307,900

Accrued Liabilities (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 2,759,400	$ 4,209,700
Professional fees	730,000	224,500
Other	1,572,400	1,628,400
Accrued Liabilities	$ 5,061,800	$ 6,062,600

Debt (Details) - USD ($)		1 Months Ended	3 Months Ended
Debt (Details) - USD ($)	Mar. 11, 2016	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 26, 2014
Debt Instrument [Line Items]
Notes Payable			$ 1,200,000			$ 1,100,000
Equity Method Investment, Ownership Percentage	19.90%
Debt Issuance Cost			(100,000)
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four			2,369,500
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Five			2,524,900
Long-term Debt			4,894,400
Interest expense			$ 100,000	$ 300,000
Impaired Long-Lived Assets Held and Used, Asset Name [Domain]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest			8.00%
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum			8.50%
Aspire Capital Purchase Agreement [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross							$ 15,000,000
NeoStem, Inc. [Member] \| Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment Terms			21 months
Oxford Finance LLC [Member]
Debt Instrument [Line Items]
Repayments of Debt	$ 7,000,000	$ 3,000,000
Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent	20.00%
Long-term Debt			$ 4,900,000		$ 5,700,000
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months			$ 3,200,000
Minimum [Member] \| Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment Terms			1 year
Maximum [Member] \| Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment Terms			3 years

Redeemable Securities (Details) - USD ($) $ in Millions	Mar. 11, 2016	Mar. 31, 2016
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage	19.90%
Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Recorded Unconditional Purchase Obligation	$ 19.4	$ 20.5
Equity Method Investment, Ownership Percentage	21.00%
Business Combination, Consideration Transfered, Interest Rate	2.00%

Shareholders' Equity - Reverse Stock Split (Details)	Jul. 28, 2016 $ / shares	Mar. 31, 2017 $ / shares	Dec. 31, 2016 $ / shares
Class of Stock [Line Items]
Common Stock, Par Value	$ 0.001	$ 0.001	$ 0.001
Reverse Stock Split, Conversion Ratio	0.1

Shareholders' Equity - Equity Issuances (Details)			1 Months Ended	3 Months Ended
Shareholders' Equity - Equity Issuances (Details)	Mar. 22, 2017 USD ($) shares	Sep. 14, 2016 USD ($) clinical_trial_subject $ / shares shares	Nov. 30, 2015 USD ($) shares	Mar. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($)	Dec. 31, 2016 shares	May 01, 2015 USD ($)
Class of Stock [Line Items]
Common Stock Warrants, Shares \| shares				336,062		388,062
Shares Issued, Price Per Share \| $ / shares		$ 4.72
Net proceeds from issuance of common stock				$ 3,241,460	$ 1,096,208
Common Stock, Shares, Issued \| shares				8,953,312		8,205,791
RD Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares	423,729	847,458
Proceeds from Issuance of Common Stock	$ 2,000,000	$ 4,000,000
Private Purchase Agreement [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock				$ 6,000,000
Proceeds from Issuance of Common Stock, Second Closing, Receivable				4,000,000
Purchase Commitment, Maximum Amount Committed, Shares \| shares		4,449,153
Proceeds from Issuance of Common Stock, Initial Closing		$ 12,600,000
Proceeds from Issuance of Common Stock, Second Closing		$ 8,400,000
Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing \| clinical_trial_subject		70
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock				$ 1,200,000
Purchase Commitment, Maximum Amount Committed, Shares \| shares			1,101,927.6
Purchase Commitment, Remaining Minimum Amount Committed			$ 30,000,000
Term of agreement in months			24 months
Stock Issued During Period, Shares, Other \| shares			84,269.6	210,506
Shares, Issued \| shares				319,776
Common Stock, Value, Issued				$ 1,500,000
Discount Applied To Weighted Average Price			5.00%
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Purchase Commitment, Remaining Minimum Amount Committed							$ 30,000,000
Common Stock, Shares, Issued \| shares				36,483.7

Shareholders' Equity - Stock options and warrants (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2017 USD ($) $ / shares $ / warrant shares	Dec. 31, 2016 USD ($) $ / shares $ / warrant shares
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 386,500	$ 0
Common Stock Warrants, Shares	336,062	388,062
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	80.40	76.50
Weighted Average Remaining Contractual Term warrant outstanding	1 year 1 month 24 days	1 year 2 months 27 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 0	$ 0
Warrants Granted	0
Warrants Canceled	(52,000)
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 0.00
Warrants Exercised	0
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 0.00
Warrants Expired	0
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 0.00
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 51.30
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 357,700
shares, vested and expected to vest	336,062
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	80.40
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 133,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	336,062
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	80.40
weighted Average Remaining Contractual Term, warrants vested	1 year 1 month 24 days
Aggregate Intrinsic Value, Warrants vested \| $	$ 0
US Equity Plan [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,133,459	952,790
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 33.30	$ 39.90
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 9 months 18 days	7 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	209,418
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 3.60
Stock Options Exercised	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 0.00
Stock Options Expired	(6,294)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	$ 8.40
Stock Options Forfeited	(22,455)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 43.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,103,988
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 34.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 9 months 4 days
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	1 year 1 month 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	821,156
Weighted average estimated fair value of shares granted \| $ / shares	$ 43.10
Options, Vested, weighted Average Remaining Contractual Term	7 years 2 months 23 days

Shareholders' Equity - Restricted Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	132,726	98,383
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 469,900	$ 562,800

Share-Based Compensation (Details) - USD ($)	3 Months Ended
Share-Based Compensation (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 533,200	$ 851,200
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 1,381,200
Expected weighted-average period in years of compensation cost to be recognized	1 year 10 months 6 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average estimated fair value of shares granted	$ 2.34	$ 4.10
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 651,500
Expected weighted-average period in years of compensation cost to be recognized	2 years 29 days
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 46,800	$ 124,300
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	52,500	92,300
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	433,900	634,600
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 507,100	$ 994,100

Research Funding (Details) - USD ($) $ in Millions	May 04, 2017	Feb. 23, 2017
Subsequent Event [Line Items]
Grants Receivable		$ 12.2
Subsequent Event [Member]
Subsequent Event [Line Items]
Grants Receivable, Current	$ 5.7

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards		$ 232,700,000
Deferred Tax Liabilities, Net, Noncurrent	$ 1,120,231	$ 1,070,700

Segment Information (Details)	3 Months Ended
Segment Information (Details)	Mar. 31, 2017 USD ($) segment	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Segment Reporting [Abstract]
Number of reportable operating segments \| segment	2
Segment Reporting Information [Line Items]
Net revenues	$ 7,922,667	$ 7,489,479
Cost of revenues	8,042,265	6,228,256
Operating Income (Loss)	(9,531,683)	(11,073,286)
Depreciation and amortization	655,300	737,200
Interest expense	167,715	926,817
Provision for income taxes	49,531	53,378
Total assets	48,528,422	63,184,900	$ 51,832,848
R&D Segment [Member]
Segment Reporting Information [Line Items]
Net revenues	0	0
Cost of revenues	0	0
Operating Income (Loss)	(7,736,600)	(10,876,300)
Depreciation and amortization	98,900	153,100
Interest expense	158,900	897,200
Provision for income taxes	0	0
Total assets	13,049,000	21,883,700
PCT Segment [Member]
Segment Reporting Information [Line Items]
Net revenues	7,922,700	7,489,500
Cost of revenues	8,042,300	6,228,300
Operating Income (Loss)	(1,795,100)	(197,000)
Depreciation and amortization	556,400	584,100
Interest expense	8,800	29,600
Provision for income taxes	49,500	53,400
Total assets	$ 35,479,500	$ 41,301,200

Commitments and Contingencies (Details) - USD ($)	3 Months Ended
Commitments and Contingencies (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 11, 2016
Operating Leased Assets [Line Items]
Equity Method Investment, Ownership Percentage			19.90%
Operating Leases, Future Minimum Payments Due [Abstract]
2016	$ 1,683,100
2017	1,723,500
2018	1,332,700
2019	792,100
2021 and thereafter	168,100
Total minimum lease payments	5,699,500
Operating lease expense	$ 500,000	$ 500,000
Hitachi Chemical Co., LTD [Member]
Operating Leased Assets [Line Items]
Recorded Unconditional Purchase Obligation		$ 20,500,000	$ 19,400,000
Equity Method Investment, Ownership Percentage			21.00%

Subsequent Events (Details) - USD ($) $ in Millions	May 04, 2017	Feb. 23, 2017
Subsequent Event [Line Items]
Grants Receivable		$ 12.2
Subsequent Event [Member]
Subsequent Event [Line Items]
Grants Receivable, Current	$ 5.7